Research programme: musculoskeletal therapeutics - Ablynx
Alternative Names: Nanobodies - AblynxLatest Information Update: 22 Jun 2018
At a glance
- Originator Ablynx; Procter & Gamble
- Developer Ablynx
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal disorders
- Discontinued Metabolic disorders
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 04 Nov 2017 No recent reports of development identified for research development in Musculoskeletal-disorders in Belgium (Parenteral)
- 23 Sep 2009 This programme is still in active development